33133-30-1

Upstream product

• 59-50-7 4-Chloro-3-methylphenol 
• 106-96-7 propargyl bromide 

Downstream Products

• 1365258-99-6 5-((4-((4-chloro-3-methylphenoxy)methyl)-1H-1,2,3-triazol-1-yl)methyl)-2-methylpyrimidin-4-amine 
• 1447169-99-4 C₂₁H₁₈Cl₂N₄O₂ 
• 1447169-79-0 C₂₁H₁₈Cl₂N₄O 
• 1430885-26-9 C₂₀H₃₂ClN₃O₇P₂ 
• 1335447-31-8 {2-[4-(4-chloro-3-methylphenoxymethyl)-[1,2,3]triazol-1-yl]ethyl}-(7-chloroquinolin-4-yl)amine 

Relevant academic research and scientific papers

1,2,3-Triazole derivatives as antitubercular agents: synthesis, biological evaluation and molecular docking study

Searching for new active molecules against Mycobacterium tuberculosis (MTB) H37Ra, a small focused library of 1,2,3-triazoles has been efficiently prepared via a click chemistry approach. The newly synthesized compounds were tested against drug-sensitive MTB. Several derivatives were found to be promising inhibitors of MTB characterized by lower MIC values (5.8-29.9 μg mL-1). Among all the synthesized 31 compounds, 15e was the most active compound against MTB. Based on the results from the anti-tubercular activity, SAR for the synthesized series has been developed. The active compounds from the anti-tubercular study were further tested for anti-proliferative activity against THP-1, A549 and PANC-1 cell lines using MTT assay and showed no significant cytotoxic activity against these three cell lines except THP-1 at the maximum concentration evaluated. Further, the synthesized compounds were found to have potential antioxidant activities with an IC50 range of 10.1-37.3 μg mL-1. The molecular docking study of the synthesized compounds was performed against the DprE1 enzyme of MTB to understand the binding interactions. Moreover, the synthesized compounds were also analysed for ADME properties and all the experimental results promote us to consider this series as a starting point for the development of novel and more potent anti-tubercular agents in the future.

Design, synthesis and biological evaluation of novel 2-methylpyrimidine-4- ylamine derivatives as inhibitors of Escherichia coli pyruvate dehydrogenase complex E1

As potential inhibitors of Escherichia coli pyruvate dehydrogenase complex E1 (PDHc E1), a series of novel 2-methylpyrimidine-4-ylamine derivatives were designed based on the structure of the active site of PDHc E1 and synthesized using 'click chemistry'.